Thermo Fisher Scientific INC

Thermo Fisher Scientific announced robust second quarter 2026 financial results, with revenue up 10% and adjusted EPS growing 13%, driven by strengthening end markets and strategic execution.

Thermo Fisher Scientific Inc. held its annual shareholder meeting on May 20, 2026, where directors were elected and the company's auditor was ratified, though a proposal on executive compensation was not approved.

Thermo Fisher Scientific reported strong first quarter 2026 financial results, with revenue growing 6% to $11.01 billion and GAAP diluted EPS increasing 11% to $4.43.

Thermo Fisher Scientific announced the completion of its acquisition of Clario Holdings, Inc. for $8.875 billion in cash, strengthening its clinical research offerings.

Thermo Fisher Scientific Inc. issued $3.8 billion in senior notes across four series to fund a significant acquisition and for general corporate purposes.

Thermo Fisher Scientific announced robust financial results for Q4 and full year 2025, driven by strategic acquisitions and product innovation.

Thermo Fisher Scientific reports strong Q2 2026 results with revenue and earnings exceeding expectations, driven by robust performance across its segments and strategic acquisitions.

Thermo Fisher Scientific reported Q1 2026 revenue of $11.0 billion, a 6% increase, driven by strong pharma and biotech demand and the acquisition of Clario Holdings.

Thermo Fisher Scientific Inc. reported a 5% increase in Q3 revenues and a 10% rise in adjusted EPS, driven by strategic acquisitions and productivity gains, despite some market headwinds.

Thermo Fisher Scientific Inc. reported a 2% increase in total revenues for the first six months of 2025, reaching $21.22 billion, alongside a 10% rise in GAAP diluted EPS, but experienced a significant 43% decline in free cash flow.

Thermo Fisher Scientific's Q1 2025 results show a slight revenue increase and reaffirmation of their growth strategy.

Thermo Fisher Scientific's third-quarter results show flat revenue growth and a decrease in earnings per share, impacted by reduced COVID-19 related demand and a muted macroeconomic environment.

Thermo Fisher Scientific Inc. announced a 4% revenue increase and 7% diluted EPS growth in its 2025 annual report, driven by strategic acquisitions and productivity gains.

Thermo Fisher Scientific's 2024 10-K filing reveals stable revenues despite a challenging macroeconomic environment and declining COVID-19 related sales, with strategic acquisitions and cost management initiatives playing key roles.

Thermo Fisher Scientific updates its by-laws and files its annual report for the fiscal year ended December 31, 2023, detailing financial results and strategic initiatives.

Gianluca Pettiti, President & COO of Thermo Fisher Scientific Inc., sold 400 shares of common stock on July 27, 2026 for $565.00 per share.

Thermo Fisher Scientific Inc. reports a director, Scott M. Sperling, acquired stock units under the company's Deferred Compensation Plan for Directors.

Thermo Fisher Scientific Inc. director Keith R. Alexandra acquired stock units under the company's Deferred Compensation Plan for Directors.

Thermo Fisher Scientific Inc. director Dion J. Weisler acquired phantom stock units under the company's Deferred Compensation Plan for Directors.

Thermo Fisher Scientific Director Karen S. Lynch acquired phantom stock units under the company's Deferred Compensation Plan for Directors.

Jennifer M. Johnson, a Director at Thermo Fisher Scientific, acquired phantom stock units valued at $60.91 on June 27, 2026, under the company's Deferred Compensation Plan for Directors.

Thermo Fisher Scientific's 2026 proxy statement details 2025 financial performance, executive compensation adjustments, and the approval of a performance-based CEO retention grant.

Thermo Fisher Scientific has filed a definitive proxy statement with the SEC.

Thermo Fisher Scientific's upcoming annual meeting will address director elections, executive compensation, auditor ratification, and a shareholder proposal regarding special meeting rights.

Thermo Fisher Scientific Inc. has filed a definitive proxy statement with the SEC.

Thermo Fisher Scientific's proxy statement outlines executive compensation, board governance practices, and proposals for the upcoming annual meeting.

Vanguard Capital Management has reported beneficial ownership of 28,008,822 shares, representing 7.53% of Thermo Fisher Scientific's common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Thermo Fisher Scientific Inc. following an internal realignment and disaggregated reporting.